Search

Your search keyword '"Spyropoulos, Alex C"' showing total 1,021 results
Start Over Author "Spyropoulos, Alex C"
1,021 results on '"Spyropoulos, Alex C"'

152. Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment

Author

Darzi, Andrea J., primary, Karam, Samer G., primary, Spencer, Frederick A., primary, Spyropoulos, Alex C., primary, Mbuagbaw, Lawrence, primary, Woller, Scott C., primary, Zakai, Neil A., primary, Streiff, Michael B., primary, Gould, Michael K., primary, Cushman, Mary, primary, Charide, Rana, primary, Etxeandia-Ikobaltzeta, Itziar, primary, Germini, Federico, primary, Rigoni, Marta, primary, Agarwal, Arnav, primary, Morsi, Rami Z., primary, Akl, Elie A., primary, Iorio, Alfonso, primary, and Schünemann, Holger J., primary

Published
2020
Full Text
View/download PDF

154. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients

Author

Spyropoulos, Alex C., primary, Ageno, Walter, additional, Albers, Gregory W., additional, Elliott, C. Gregory, additional, Halperin, Jonathan L., additional, Hiatt, William R., additional, Maynard, Gregory A., additional, Steg, P. Gabriel, additional, Weitz, Jeffrey I., additional, Lu, Wentao, additional, Spiro, Theodore E., additional, Barnathan, Elliot S., additional, and Raskob, Gary. E., additional

Published
2020
Full Text
View/download PDF

155. Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis

Author

Darzi, Andrea J., primary, Karam, Samer G., primary, Charide, Rana, primary, Etxeandia-Ikobaltzeta, Itziar, primary, Cushman, Mary, primary, Gould, Michael K., primary, Mbuagbaw, Lawrence, primary, Spencer, Frederick A., primary, Spyropoulos, Alex C., primary, Streiff, Michael B., primary, Woller, Scott, primary, Zakai, Neil A., primary, Germini, Federico, primary, Rigoni, Marta, primary, Agarwal, Arnav, primary, Morsi, Rami Z., primary, Iorio, Alfonso, primary, Akl, Elie A., primary, and Schünemann, Holger J., primary

Published
2020
Full Text
View/download PDF

161. Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials

Author

Weitz, Jeffrey I., additional, Raskob, Gary E., additional, Spyropoulos, Alex C., additional, Spiro, Theodore E., additional, De Sanctis, Yoriko, additional, Xu, Jianfeng, additional, Lu, Wentao, additional, Suh, Eunyoung, additional, Argenti, Domenick, additional, Yang, Haitao, additional, Albanese, John, additional, Lipardi, Concetta, additional, and Barnathan, Elliot S., additional

Published
2020
Full Text
View/download PDF

167. Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial.

Author

Goldenberg, Neil A., Kittelson, John M., Abshire, Thomas C., Bonaca, Marc, Casella, James F., Dale, Rita A., Halperin, Jonathan L., Hamblin, Frances, Kessler, Craig M., Manco-Johnson, Marilyn J., Sidonio, Robert F., Spyropoulos, Alex C., Steg, P. Gabriel, Turpie, Alexander G. G., Schulman, Sam, and Kids-DOTT Trial Investigators and the ATLAS Group

Subjects
ANTICOAGULANTS, THROMBOEMBOLISM, HEMORRHAGE, EMBOLISMS, CLINICAL trials, THERAPEUTICS, RESEARCH, VEINS, AGE distribution, TIME, RESEARCH methodology, DISEASE incidence, EVALUATION research, DRUG administration, DISEASE relapse, COMPARATIVE studies, RANDOMIZED controlled trials, KAPLAN-Meier estimator, RESEARCH funding, STATISTICAL sampling, LONGITUDINAL method
Abstract

Importance: Among patients younger than 21 years of age, the optimal duration of anticoagulant therapy for venous thromboembolism is unknown.Objective: To test the hypothesis that a 6-week duration of anticoagulant therapy for provoked venous thromboembolism is noninferior to a conventional 3-month therapy duration in patients younger than 21 years of age.Design, Setting, and Participants: Randomized clinical trial involving 417 patients younger than 21 years of age with acute, provoked venous thromboembolism enrolled at 42 centers in 5 countries from 2008-2021. The main exclusions were severe anticoagulant deficiencies or prior venous thromboembolism. Patients without persistent antiphospholipid antibodies and whose thrombi were resolved or not completely occlusive upon repeat imaging at 6 weeks after diagnosis underwent randomization. The final visit for the primary end points occurred in January 2021.Interventions: Total duration for anticoagulant therapy of 6 weeks (n = 207) vs 3 months (n = 210) for provoked venous thromboembolism.Main Outcomes and Measures: The primary efficacy and safety end points were centrally adjudicated symptomatic recurrent venous thromboembolism and clinically relevant bleeding events within 1 year blinded to treatment group. The primary analysis was noninferiority in the per-protocol population. The noninferiority boundary incorporated a bivariate trade-off that included an absolute increase of 0% in symptomatic recurrent venous thromboembolism with an absolute risk reduction of 4% in clinically relevant bleeding events (1 of 3 points on the bivariate noninferiority boundary curve).Results: Among 417 randomized patients, 297 (median age, 8.3 [range, 0.04-20.9] years; 49% female) met criteria for the primary per-protocol population analysis. The Kaplan-Meier estimate for the 1-year cumulative incidence of the primary efficacy outcome was 0.66% (95% CI, 0%-1.95%) in the 6-week anticoagulant therapy group and 0.70% (95% CI, 0%-2.07%) in the 3-month anticoagulant therapy group, and for the primary safety outcome, the incidence was 0.65% (95% CI, 0%-1.91%) and 0.70% (95% CI, 0%-2.06%). Based on absolute risk differences in recurrent venous thromboembolism and clinically relevant bleeding events between groups, noninferiority was demonstrated. Adverse events occurred in 26% of patients in the 6-week anticoagulant therapy group and in 32% of patients in the 3-month anticoagulant therapy group; the most common adverse event was fever (1.9% and 3.4%, respectively).Conclusions and Relevance: Among patients younger than 21 years of age with provoked venous thromboembolism, anticoagulant therapy for 6 weeks compared with 3 months met noninferiority criteria based on the trade-off between recurrent venous thromboembolism risk and bleeding risk.Trial Registration: ClinicalTrials.gov Identifier: NCT00687882. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

168. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.

Author

Spyropoulos, Alex C., Goldin, Mark, Giannis, Dimitrios, Diab, Wassim, Wang, Janice, Khanijo, Sameer, Mignatti, Andrea, Gianos, Eugenia, Cohen, Marc, Sharifova, Gulru, Lund, Jeet M., Tafur, Alfonso, Lewis, Paul A., Cohoon, Kevin P., Rahman, Husneara, Sison, Cristina P., Lesser, Martin L., Ochani, Kanta, Agrawal, Nirav, and Hsia, Judith

Published
2021
Full Text
View/download PDF

172. Supplemental Material, Spyropoulos.Supplementary_14_Aug_2019_final - Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study

Author

Spyropoulos, Alex C., Lipardi, Concetta, Jianfeng Xu, Wentao Lu, Eunyoung Suh, Yuan, Zhong, Levitan, Bennett, Sugarmann, Chiara, Sanctis, Yoriko De, Spiro, Theodore E., Barnathan, Elliot S., and Raskob, Gary E.

Subjects
FOS: Clinical medicine, Cardiology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
Abstract

Supplemental Material, Spyropoulos.Supplementary_14_Aug_2019_final for Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study by Alex C. Spyropoulos, Concetta Lipardi, Jianfeng Xu, Wentao Lu, Eunyoung Suh, Zhong Yuan, Bennett Levitan, Chiara Sugarmann, Yoriko De Sanctis, Theodore E. Spiro, Elliot S. Barnathan and Gary E. Raskob in Clinical and Applied Thrombosis/Hemostasis

Published
2019
Full Text
View/download PDF

173. Epidemiology of venous thromboembolism in cardiorespiratory and infectious disease

Author

Alikhan, Raza and Spyropoulos, Alex C.

Subjects
Thromboembolism -- Complications and side effects, Thromboembolism -- Drug therapy, Venous thrombosis -- Prevention, Pulmonary embolism -- Prevention, Health, Health care industry
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjmed.2008.05.045 Byline: Raza Alikhan (a), Alex C. Spyropoulos (b) Keywords: Chronic obstructive pulmonary disease; Deep vein thrombosis; Epidemiology; Heart failure; Infection; Pulmonary embolism; Thromboprophylaxis; Venous thromboembolism Abstract: Venous thromboembolic complications -- deep vein thrombosis and pulmonary embolism -- occur in a significant proportion of hospitalized medical patients. The incidence in acutely ill medical patients is 10%-40%, equivalent to that seen in general surgical patients. Prophylaxis is effective and well tolerated, yet remains under-prescribed in medical wards. Current recommendations for prophylaxis are generalized and do not specifically address many patient groups. Data on the prevalence in patients with chronic obstructive pulmonary disease, heart failure, and infectious diseases are limited. However, studies on large numbers of hospitalized patients with these admission diagnoses have provided important information on incidence, and the efficacy of thromboprophylaxis. This review summarizes current knowledge of the epidemiology of venous thromboembolism in patients with chronic obstructive pulmonary disease, heart failure, and infectious diseases, and highlights the benefits of, and needs for, appropriate prophylaxis in these groups. Increased awareness of the prevalence of thrombosis in the major subgroups of medical inpatients should improve the prescribing of prophylaxis and prevent potentially avoidable and costly complications. Author Affiliation: (a) Department of Haematology, John Radcliffe Hospital, Oxford, UK (b) Clinical Thrombosis Center, Lovelace Medical Center, Albuquerque, NM

Published
2008

174. Venous Thromboembolism Prophylaxis in Acutely Ill Hospitalized Medical Patients*: Findings From the International Medical Prevention Registry on Venous Thromboembolism

Author

Tapson, Victor F., Decousus, Hervé, Pini, Mario, Chong, Beng H., Froehlich, James B., Monreal, Manuel, Spyropoulos, Alex C., Merli, Geno J., Zotz, Rainer B., Bergmann, Jean-François, Pavanello, Ricardo, Turpie, Alexander G.G., Nakamura, Mashio, Piovella, Franco, Kakkar, Ajay K., Spencer, Frederick A., FitzGerald, Gordon, and Anderson, Frederick A., Jr

Published
2007
Full Text
View/download PDF

175. Introduction

Author

SPYROPOULOS, ALEX C.

Published
2006

184. The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper.

Author

Gerotziafas, Grigoris T., Catalano, Mariella, Theodorou, Yiannis, Dreden, Patrick Van, Marechal, Vincent, Spyropoulos, Alex C., Carter, Charles, Jabeen, Nusrat, Harenberg, Job, Elalamy, Ismail, Falanga, Anna, Fareed, Jawed, Agathaggelou, Petros, Antic, Darko, Antignani, Pier Luigi, Bosch, Manuel Monreal, Brenner, Benjamin, Chekhonin, Vladimir, Colgan, Mary-Paula, and Dimopoulos, Meletios-Athanasios

Published
2021
Full Text
View/download PDF

188. SUPPLEMENTAL_APPENDIX - Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism

Author

Coleman, Craig I., Beyer-Westendorf, Jan, Bunz, Thomas J., Mahan, Charles E., and Spyropoulos, Alex C.

Subjects
FOS: Clinical medicine, Cardiology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
Abstract

SUPPLEMENTAL_APPENDIX for Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism by Craig I. Coleman, Jan Beyer-Westendorf, Thomas J. Bunz, Charles E. Mahan, and Alex C. Spyropoulos in Clinical and Applied Thrombosis/Hemostasis

Published
2018
Full Text
View/download PDF

190. Association of Bleeding Severity with Mortality with Extended Thromboprophylaxis in the Medically Ill in the Mariner Trial

Author

Spyropoulos, Alex C., primary, Ageno, Walter, additional, Albers, Gregory W., additional, Elliott, C. Gregory, additional, Halperin, Jonathan L., additional, Hiatt, William R., additional, Maynard, Gregory, additional, Steg, P. Gabriel, additional, Weitz, Jeffrey I., additional, Spiro, Theodore E., additional, Lu, Wentao, additional, Sugarmann, Chiara, additional, Lipardi, Concetta, additional, Raskob, Gary E., additional, and Barnathan, Elliot S., additional

Published
2019
Full Text
View/download PDF

192. Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study

Author

Raskob, Gary E., primary, Spyropoulos, Alex C., primary, Cohen, Alexander T, primary, Weitz, Jeffrey I., primary, Ageno, Walter, primary, De Sanctis, Yoriko, primary, Lu, Wentao, primary, Xu, Jianfeng, primary, Albanese, John, primary, Sugarmann, Chiara, primary, Lipardi, Concetta, primary, Spiro, Theodore E., primary, and Barnathan, Elliot S., primary

Published
2019
Full Text
View/download PDF

193. Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: Recommendations for standardized reporting of procedural/surgical bleed risk and patient‐specific thromboembolic risk

Author

Spyropoulos, Alex C., primary, Brohi, Karim, additional, Caprini, Joseph, additional, Samama, Charles Marc, additional, Siegal, Deborah, additional, Tafur, Alfonso, additional, Verhamme, Peter, additional, and Douketis, James D., additional

Published
2019
Full Text
View/download PDF

194. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant

Author

Douketis, James D., primary, Spyropoulos, Alex C., additional, Duncan, Joanne, additional, Carrier, Marc, additional, Le Gal, Gregoire, additional, Tafur, Alfonso J., additional, Vanassche, Thomas, additional, Verhamme, Peter, additional, Shivakumar, Sudeep, additional, Gross, Peter L., additional, Lee, Agnes Y. Y., additional, Yeo, Erik, additional, Solymoss, Susan, additional, Kassis, Jeannine, additional, Le Templier, Geneviève, additional, Kowalski, Stephen, additional, Blostein, Mark, additional, Shah, Vinay, additional, MacKay, Elizabeth, additional, Wu, Cynthia, additional, Clark, Nathan P., additional, Bates, Shannon M., additional, Spencer, Frederick A., additional, Arnaoutoglou, Eleni, additional, Coppens, Michiel, additional, Arnold, Donald M., additional, Caprini, Joseph A., additional, Li, Na, additional, Moffat, Karen A., additional, Syed, Summer, additional, and Schulman, Sam, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results